These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10895868)

  • 1. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy.
    Andersen S; Schalkwijk CG; Stehouwer CD; Parving HH
    Diabetes Care; 2000 Jul; 23(7):1031-2. PubMed ID: 10895868
    [No Abstract]   [Full Text] [Related]  

  • 2. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K; Christensen PK; Jensen BR; Parving HH
    Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis.
    Prasad A; Koh KK; Schenke WH; Mincemoyer R; Csako G; Fleischer TA; Brown M; Selvaggi TA; Quyyumi AA
    Am Heart J; 2001 Aug; 142(2):248-53. PubMed ID: 11479463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1.
    Jilma B; Li-Saw-Hee FL; Wagner OF; Beevers DG; Lip GY
    Clin Sci (Lond); 2002 Aug; 103(2):131-6. PubMed ID: 12149103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
    Agarwal R
    Am J Physiol Renal Physiol; 2003 Apr; 284(4):F863-9. PubMed ID: 12505865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockade decreases markers of vascular inflammation.
    Graninger M; Reiter R; Drucker C; Minar E; Jilma B
    J Cardiovasc Pharmacol; 2004 Sep; 44(3):335-9. PubMed ID: 15475831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
    Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current controversies in blood pressure in diabetic nephropathy.
    Ritz E; Schömig M
    Curr Hypertens Rep; 1999; 1(1):9-10. PubMed ID: 10981035
    [No Abstract]   [Full Text] [Related]  

  • 10. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy.
    Kuriyama S; Tomonari H; Abe A; Imasawa T; Hosoya T
    Nephron; 2000 Dec; 86(4):529-30. PubMed ID: 11124615
    [No Abstract]   [Full Text] [Related]  

  • 12. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C; Schernthaner G
    Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy.
    Hebert LA; Falkenhain ME; Nahman NS; Cosio FG; O'Dorisio TM
    Am J Nephrol; 1999; 19(1):1-6. PubMed ID: 10085442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy].
    Nitschmann S; Girndt M; Köhler H
    Internist (Berl); 2005 Aug; 46(8):923-4, 926. PubMed ID: 15990988
    [No Abstract]   [Full Text] [Related]  

  • 16. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic nephropathy: evidence for renoprotection and practice.
    Mogensen CE
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i26-8:discussion i50. PubMed ID: 10956317
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice.
    Yotsumoto T; Naitoh T; Shikada K; Tanaka S
    Jpn J Pharmacol; 1997 Sep; 75(1):59-64. PubMed ID: 9334886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.